MannKind's (MNKD) stock surged 73%, driven by its 9% royalty stake in Tyvaso DPI. It has strong liquidity. Click here to see ...
MannKind announced top-level 30-week results from its Phase 4 INHALE-3 study comparing inhaled insulin to traditional ...
Zacks.com on MSN3d
MannKind (MNKD) Just Overtook the 20-Day Moving AverageWhen a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD), a biopharmaceutical company specializing in inhaled therapeutic products, has been making significant strides in its core business areas while ...
MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...
On Monday, MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.29 which represents a slight increase of $0.09 or 1.45% from the prior close of $6.2. The stock opened at $6.16 and ...
MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD), a biopharmaceutical company specializing in inhaled therapeutic products, has been making significant strides in its core business areas while facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback